Telomerase as drug and drug target for the treatment of thyroid cancer

M. A. Zeiger, A. K. Meeker

Research output: Contribution to journalReview articlepeer-review


Telomerase is known to be activated in almost all cancer cells and is quiescent in almost all normal cells. Therefore, it follows that therapeutic strategies directed against cancer would include the targeting of telomerase, as well as the use of telomerase. Several approaches have been used both in vitro and in vivo and include the following: 1) antisense; 2) immunotherapy directed against hTERT; and 3) the use of telomerase promoter to direct cytotoxic therapy. Herein we review these approaches and discuss their potential applicability against thyroid cancer.

Original languageEnglish (US)
Pages (from-to)253-256
Number of pages4
JournalCurrent Drug Targets: Immune, Endocrine and Metabolic Disorders
Issue number3
StatePublished - Sep 1 2004


  • Antisense strategy
  • Drug target
  • Immunotherapy
  • Telomerase
  • Thyroid cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy


Dive into the research topics of 'Telomerase as drug and drug target for the treatment of thyroid cancer'. Together they form a unique fingerprint.

Cite this